Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
NCT06240143Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2024
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in melanoma, sponsored by Netherlands Cancer Institute. Started Mar 2024; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06240143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06240143.